Literature DB >> 24352218

Macrovascular involvement in a child with atypical hemolytic uremic syndrome.

Karolis Ažukaitis1, Chantal Loirat, Michal Malina, Irina Adomaitienė, Augustina Jankauskienė.   

Abstract

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a disorder of the complement system which leads to thrombotic microangiopathy. It is caused by either acquired or hereditary defects in the activation or regulation of the alternative complement pathway and is therefore considered to be a disease of local complement dysregulation in microvasculature with predominantly renal involvement. However, extrarenal manifestations are observed in approximately one-fifth of aHUS patients, with the myocardium and central nervous system (CNS) being involved most often. Additionally, there have been a few reports of aHUS with cerebral artery stenoses or periphereal gangrene, suggesting the possibility of 'macrovascular' involvement in aHUS. CASE-DIAGNOSIS/TREATMENT: We present a child with early onset aHUS and a C3 gain-of-function mutation who developed cerebral artery stenoses, leading ultimately to death due to a massive stroke 9 days after successful renal transplantation under prophylactic eculizumab treatment. Similar cases described in the literature are also briefly summarized.
CONCLUSIONS: The disease course in our patient with aHUS confirms that dysregulated complement activation can induce arterial steno-occlusive lesions in the absence of acute episodes of HUS. Further studies are required to document the frequency of such macrovascular complications and the role of eculizumab treatment in preventing their development and progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352218     DOI: 10.1007/s00467-013-2713-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  27 in total

1.  Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation.

Authors:  Chantal Loirat; Marie-Alice Macher; Monique Elmaleh-Berges; Theresa Kwon; Georges Deschênes; Timothy H J Goodship; Charles Majoie; Jean-Claude Davin; Raphael Blanc; Julien Savatovsky; Jacques Moret; Véronique Fremeaux-Bacchi
Journal:  Nephrol Dial Transplant       Date:  2010-06-08       Impact factor: 5.992

2.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

3.  Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.

Authors:  Gema Ariceta; Beatriz Arrizabalaga; Mireia Aguirre; Elvira Morteruel; Margarita Lopez-Trascasa
Journal:  Am J Kidney Dis       Date:  2011-12-23       Impact factor: 8.860

4.  Neurological involvement in a child with atypical hemolytic uremic syndrome.

Authors:  Bérengère Koehl; Olivia Boyer; Nathalie Biebuyck-Gougé; Manoelle Kossorotoff; Véronique Frémeaux-Bacchi; Nathalie Boddaert; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2010-08-17       Impact factor: 3.714

5.  Moyamoya vasculopathy in a child after hemolytic uremic syndrome: a possible etiopathogenesis.

Authors:  M Singla; E John; G Hidalgo; D Grewal; C Macmillan
Journal:  Neuropediatrics       Date:  2008-04       Impact factor: 1.947

6.  Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.

Authors:  Jean-Claude Davin; Valentina Gracchi; Antonia Bouts; Jaap Groothoff; Lisa Strain; Tim Goodship
Journal:  Am J Kidney Dis       Date:  2009-10-25       Impact factor: 8.860

7.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

8.  Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.

Authors:  Lubka T Roumenina; Mathieu Jablonski; Christophe Hue; Jacques Blouin; Jordan D Dimitrov; Marie-Agnes Dragon-Durey; Mathieu Cayla; Wolf H Fridman; Marie-Alice Macher; David Ribes; Luc Moulonguet; Lionel Rostaing; Simon C Satchell; Peter W Mathieson; Catherine Sautes-Fridman; Chantal Loirat; Catherine H Regnier; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi
Journal:  Blood       Date:  2009-07-07       Impact factor: 22.113

9.  Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

Authors:  J Zuber; M Le Quintrec; S Krid; C Bertoye; V Gueutin; A Lahoche; N Heyne; G Ardissino; V Chatelet; L-H Noël; M Hourmant; P Niaudet; V Frémeaux-Bacchi; E Rondeau; C Legendre; C Loirat
Journal:  Am J Transplant       Date:  2012-09-07       Impact factor: 8.086

10.  Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.

Authors:  Mathieu Lemaire; Véronique Frémeaux-Bacchi; Franz Schaefer; Murim Choi; Wai Ho Tang; Moglie Le Quintrec; Fadi Fakhouri; Sophie Taque; François Nobili; Frank Martinez; Weizhen Ji; John D Overton; Shrikant M Mane; Gudrun Nürnberg; Janine Altmüller; Holger Thiele; Denis Morin; Georges Deschenes; Véronique Baudouin; Brigitte Llanas; Laure Collard; Mohammed A Majid; Eva Simkova; Peter Nürnberg; Nathalie Rioux-Leclerc; Gilbert W Moeckel; Marie Claire Gubler; John Hwa; Chantal Loirat; Richard P Lifton
Journal:  Nat Genet       Date:  2013-03-31       Impact factor: 41.307

View more
  14 in total

1.  Complement factor B mutation-associated aHUS and myocardial infarction.

Authors:  Natália Noronha; Filipa Dias Costa; Andrea Dias; Alexandra Dinis
Journal:  BMJ Case Rep       Date:  2017-07-14

Review 2.  Cardiovascular complications in atypical haemolytic uraemic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

Review 3.  Current treatment of atypical hemolytic uremic syndrome.

Authors:  Bernard S Kaplan; Rebecca L Ruebner; Joann M Spinale; Lawrence Copelovitch
Journal:  Intractable Rare Dis Res       Date:  2014-05

Review 4.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

5.  Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Authors:  Elizabeth C Schramm; Lubka T Roumenina; Tania Rybkine; Sophie Chauvet; Paula Vieira-Martins; Christophe Hue; Tara Maga; Elisabetta Valoti; Valerie Wilson; Sakari Jokiranta; Richard J H Smith; Marina Noris; Tim Goodship; John P Atkinson; Veronique Fremeaux-Bacchi
Journal:  Blood       Date:  2015-01-21       Impact factor: 22.113

6.  Identification of discriminative gene-level and protein-level features associated with pathogenic gain-of-function and loss-of-function variants.

Authors:  Cigdem Sevim Bayrak; David Stein; Aayushee Jain; Kumardeep Chaudhary; Girish N Nadkarni; Tielman T Van Vleck; Anne Puel; Stephanie Boisson-Dupuis; Satoshi Okada; Peter D Stenson; David N Cooper; Avner Schlessinger; Yuval Itan
Journal:  Am J Hum Genet       Date:  2021-11-10       Impact factor: 11.043

7.  Rapid conditional targeted ablation model for hemolytic anemia in the rat.

Authors:  Marina M Hanson; Fengming Liu; Shen Dai; Alison Kearns; Xuebin Qin; Elizabeth C Bryda
Journal:  Physiol Genomics       Date:  2016-07-01       Impact factor: 3.107

8.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Authors:  Christoph Licht; Larry A Greenbaum; Petra Muus; Sunil Babu; Camille L Bedrosian; David J Cohen; Yahsou Delmas; Kenneth Douglas; Richard R Furman; Osama A Gaber; Timothy Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe M Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

9.  New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3.

Authors:  Elizabeth Rodriguez; Pavithra M Rallapalli; Amy J Osborne; Stephen J Perkins
Journal:  Biosci Rep       Date:  2014-10-22       Impact factor: 3.840

Review 10.  Extra-renal manifestations of complement-mediated thrombotic microangiopathies.

Authors:  Johannes Hofer; Alejandra Rosales; Caroline Fischer; Thomas Giner
Journal:  Front Pediatr       Date:  2014-09-08       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.